Korro Bio, Inc.
For the period ended Nov 3, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 3, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
KRRO$14.75+0.1%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Additional Pipeline Programs
Additional Pipeline Programs
Continued preclinical development of OPERA-derived REOs targeting AMPKγ1 for longevity and TDP-43 for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.